At the American Association for Cancer Research (AACR) Annual Meeting 2022, we’re presenting new clinical and preclinical data for multiple programs across our precision therapy portfolio, highlighting our goal to bring the promise of precision medicine to broad patient populations with genomically defined cancers, including lung, ovarian and breast cancers.
Hear more from our scientific and clinical development experts:
Fouad Namouni, M.D., President of Research & Development
Brenton Mar, M.D., Ph.D., Vice President of Clinical Development, and Chiara Conti, Ph.D., Director of Biology, on our programs for EGFR-mutant non-small cell lung cancer
Brenton Mar, M.D., Ph.D., Vice President of Clinical Development, and Chiara Conti, Ph.D., Director of Biology, on our programs for EGFR-mutant non-small cell lung cancer
Maria Roche, Vice President of Clinical Development, and Victoria Brown, Senior Scientist in Biology, on our program for cyclin E aberrant cancers
Maria Roche, Vice President of Clinical Development, and Victoria Brown, Senior Scientist in Biology, on our program for cyclin E aberrant cancers